-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, competition in the domestic PD-1 market has become increasingly fierce
.
It is reported that there are currently as many as 6 domestically produced PD-1s on the market in China, namely Hengrui’s Karelizumab, BeiGene’s Tilelizumab, Xinda Bio’s Sintilizumab, and Jun Real Biotech’s Teriprolizumab, Kangfang Bio’s Paimrizumab and Yuheng Biotech Sepalizumab, of which the latter two are all newly approved products for marketing in 2021, while the first four are All have entered medical insurance through price cuts
.
It is worth noting that, in addition, there are incomplete statistics showing that as of February 2021, there are 154 PD-1 monoclonal antibodies under research worldwide, of which 85 are developed or jointly developed by Chinese companies, accounting for Reach 55%
.
In this regard, the industry believes that as local pharmaceutical companies continue to enter the PD-1 field, competition in this market will become more intense
.
Then, under the gradual duplication and homogeneity of PD-1 new drug research, and the increasing pressure of centralized procurement, how can domestic related companies avoid internal roll-out? From the current point of view, the industry believes that domestic PD-1 companies are setting their sights on overseas markets
.
For example, Bright Peak Therapeutics of the United States announced to the public that Livzonumab, a subsidiary of Livzon Group, has signed a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States.
Livzonumab will have independent intellectual property rights.
Recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection is licensed to BPTx for the development of new PD-1 targeted immune cytokines (PD-1 ICs) with a paid non-exclusive license, and licenses LZM009 to BPTx for use in removing large Development and commercialization of PD-1 ICs drugs outside of China
.
Data show that LZM009 is a new drug variety with independent intellectual property rights for Livzonumab.
The molecular sequence and use patents of this variety have been applied for Chinese and PCT patents
.
Livzonumab formally submitted to the FDA the clinical trial application of "Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection" on June 29, 2017 U.
S.
time and was accepted, and on July 28, 2017 U.
S.
time Obtained official FDA approval
.
In fact, in the same year, Livzonumab had already licensed the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeting Immune cytokines (PD-1 ICs), and authorized LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China
.
It is worth mentioning that, in fact, the overseas launch of Livzonumab PD-1 is another Chinese pharmaceutical company following the overseas launch of PD-1/L1 developed by Cinda Biologicals, BeiGene, and CStone Pharmaceuticals.
PD-1’s going to sea
.
It is understood that there are currently 13 PD-1/L1 projects that have been publicly disclosed and licensed out by domestic pharmaceutical companies
.
The analysis believes that, from the above point of view, it has become the consensus of many pharmaceutical companies to promote the export of domestic PD-1 monoclonal antibodies
.
In the future, in the case of domestic PD-1 competition becoming more fierce and prices falling, the development of overseas rights and interests, with the help of partners' mature overseas sales channels, is expected to become a new way for more and more domestic pharmaceutical companies to expand the market
.
.
It is reported that there are currently as many as 6 domestically produced PD-1s on the market in China, namely Hengrui’s Karelizumab, BeiGene’s Tilelizumab, Xinda Bio’s Sintilizumab, and Jun Real Biotech’s Teriprolizumab, Kangfang Bio’s Paimrizumab and Yuheng Biotech Sepalizumab, of which the latter two are all newly approved products for marketing in 2021, while the first four are All have entered medical insurance through price cuts
.
It is worth noting that, in addition, there are incomplete statistics showing that as of February 2021, there are 154 PD-1 monoclonal antibodies under research worldwide, of which 85 are developed or jointly developed by Chinese companies, accounting for Reach 55%
.
In this regard, the industry believes that as local pharmaceutical companies continue to enter the PD-1 field, competition in this market will become more intense
.
Then, under the gradual duplication and homogeneity of PD-1 new drug research, and the increasing pressure of centralized procurement, how can domestic related companies avoid internal roll-out? From the current point of view, the industry believes that domestic PD-1 companies are setting their sights on overseas markets
.
For example, Bright Peak Therapeutics of the United States announced to the public that Livzonumab, a subsidiary of Livzon Group, has signed a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States.
Livzonumab will have independent intellectual property rights.
Recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection is licensed to BPTx for the development of new PD-1 targeted immune cytokines (PD-1 ICs) with a paid non-exclusive license, and licenses LZM009 to BPTx for use in removing large Development and commercialization of PD-1 ICs drugs outside of China
.
Data show that LZM009 is a new drug variety with independent intellectual property rights for Livzonumab.
The molecular sequence and use patents of this variety have been applied for Chinese and PCT patents
.
Livzonumab formally submitted to the FDA the clinical trial application of "Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection" on June 29, 2017 U.
S.
time and was accepted, and on July 28, 2017 U.
S.
time Obtained official FDA approval
.
In fact, in the same year, Livzonumab had already licensed the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeting Immune cytokines (PD-1 ICs), and authorized LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China
.
It is worth mentioning that, in fact, the overseas launch of Livzonumab PD-1 is another Chinese pharmaceutical company following the overseas launch of PD-1/L1 developed by Cinda Biologicals, BeiGene, and CStone Pharmaceuticals.
PD-1’s going to sea
.
It is understood that there are currently 13 PD-1/L1 projects that have been publicly disclosed and licensed out by domestic pharmaceutical companies
.
The analysis believes that, from the above point of view, it has become the consensus of many pharmaceutical companies to promote the export of domestic PD-1 monoclonal antibodies
.
In the future, in the case of domestic PD-1 competition becoming more fierce and prices falling, the development of overseas rights and interests, with the help of partners' mature overseas sales channels, is expected to become a new way for more and more domestic pharmaceutical companies to expand the market
.
